Tissue Biopsies

PROCEDURE4 trials

Sponsors

University Hospital Center of Martinique, University Hospital, Lille, Highlight Therapeutics, Clinica Universidad de Navarra, Universidad de Navarra

Conditions

Left Ventricular HypertrophyLung CancerMelanomaNon-Small Cell Lung Cancer Metastatic

Phase 1

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Clinica Universidad de Navarra, Universidad de NavarraNon-Small Cell Lung Cancer Metastatic

Start: 2022-06-13End: 2024-06-30Target: 30Updated: 2022-07-19

Phase 2

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

CompletedNCT04570332

Highlight TherapeuticsMelanoma

Start: 2020-12-30End: 2024-11-04Updated: 2025-11-26

Unknown Phase

Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)

CompletedNCT03322319

University Hospital Center of MartiniqueLeft Ventricular Hypertrophy

Start: 2013-09-23End: 2016-01-18Updated: 2017-10-27

A Clinico-biological Database of Lung Cancers

RecruitingNCT03387865

University Hospital, LilleLung Cancer

Start: 2019-03-13End: 2032-03-31Target: 500Updated: 2022-10-19

Related Papers

BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

Journal of Clinical Oncology2025-06-273 citations

Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study

Cancer Research2022-06-156 citations

Abstract CT107: Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma

Cancer Research2022-06-15

Abstract CT109: Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma

Cancer Research2022-06-15

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

2021-11-018 citations

Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Cancer Research2021-07-012 citations

Abstract 1790: BO-112 as a modifier of the tumor microenvironment for liver metastases

Cancer Research2021-07-01

Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.

Journal of Clinical Oncology2021-05-203 citations